Equities

Transcenta Holding Limited

Transcenta Holding Limited

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.82
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change-57.41%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2022 07:33 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Transcenta Holding Limited is a China-based investment holding company engaged in the discovery, research, development, manufacturing and business development of biopharmaceuticals in the clinical stage. The Company's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The Company's all products are in the research and development (R&D) stage and have not been commercialized. The Company also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.

  • Revenue in HKD (TTM)49.49m
  • Net income in HKD-1.01bn
  • Incorporated2010
  • Employees321.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Canbridge Pharmaceuticals Inc58.64m-1.07bn1.10bn141.00--1.99--18.81-12.24-12.240.23781.300.0773.604.95320,429.70-140.88---182.11--63.51---1,828.44--3.00-506.820.2359--158.98---27.30------
Genor Biopharma Holdings Ltd3.23m-950.02m1.15bn452.00--0.4955--355.14-1.90-1.900.00654.580.0010.01750.0295,043.80-30.50---33.43--73.38---29,412.99--8.33--0.0252---100.00--71.42------
Hbm Holdings Ltd232.10m-1.17bn1.19bn365.00--0.9398--5.13-1.59-1.590.31631.650.0998--25.77602,858.80-50.15---57.13--99.31---502.40------0.2826---69.46--53.52------
Zhaoke Ophthalmology Ltd0.00-331.05m1.27bn268.00--0.4698-----0.6111-0.61110.004.980.00----0.00-11.24---11.70-------------127.180.0247-------192.96------
Golden Throat Holdings Group Co Ltd829.25m177.85m1.29bn937.007.230.89635.871.550.24060.24061.121.940.42312.583.17885,003.009.078.5712.6412.0269.6972.6821.4518.782.38159.040.180656.2526.831.3321.8012.7644.8222.25
Jacobson Pharma Corporation Ltd1.60bn177.67m1.62bn1.74k9.060.64594.271.020.09270.09270.83291.300.33162.915.60919,091.603.904.965.376.8838.8941.4111.7613.741.0516.360.322832.4610.354.902.28-0.186-7.1112.02
Mabpharm Ltd33.29m-287.63m1.69bn389.00--3.15--50.79-0.0697-0.06970.00810.130.03180.18753.9868,777.45-27.48---35.08--63.71---864.06--0.6451-32.370.205-------58.01------
Dawnrays Pharmaceutical Holdings Ltd1.29bn396.61m1.69bn1.06k4.300.62713.661.310.26310.26310.8551.800.38392.397.001,209,992.0011.7211.4513.9513.8359.2658.7130.5329.602.3120.120.010542.6813.757.1733.586.1465.212.29
JW (Cayman) Therapeutics Co Ltd105.71m-929.19m1.70bn589.00--0.5983--16.10-2.29-2.290.26026.920.03043.112.83197,963.80-26.67---28.28--33.24---878.98--9.74-10.520.0545------57.79------
Transcenta Holding Limited49.49m-1.01bn1.70bn321.00--0.8844--34.39-2.28-2.280.11244.320.01941.654.56136,323.00-39.61---48.08--17.48---2,040.65--2.63-47.970.1908---37.96---441.82------
TOT Biopharm International Co Ltd256.86m-176.84m1.73bn355.00--3.88--6.73-0.3074-0.30740.44650.58250.32541.655.40762,190.20-22.41---34.33--73.14---68.85--0.8533-14.000.4296--239.36--9.46------
Essex Bio-Technology Ltd1.56bn323.01m1.82bn1.42k5.861.055.061.170.54270.54272.593.040.5751.873.021,128,434.0011.9414.0515.5818.5387.3882.6320.7621.202.0019.460.227215.5767.4316.1258.0320.4847.8724.31
SinoMab Bioscience Ltd28.30m-346.81m1.91bn296.00--3.00--67.66-0.351-0.3510.02860.61720.0264----99,991.95-32.38---34.63-------1,225.57-----6.780.3432-------135.07------
Abbisko Cayman Ltd-100.00bn-100.00bn2.45bn192.00--0.9038----------3.86----------------------------0.0204-------156.14------
Antengene Corporation Ltd90.34m-619.16m2.47bn383.00--1.03--27.36-0.9937-0.99370.14533.630.03072.901.68274,583.60-21.02---22.36--83.94---685.39--11.13--0.0156------77.62------
Immunotech Biopharm Ltd0.00-379.21m2.49bn267.00--3.32-----0.7369-0.73690.001.450.00----0.00-33.66---37.53----------1.49-18.730.1291------19.32------
Data as of Nov 25 2022. Currency figures normalised to Transcenta Holding Limited's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

8.16%Per cent of shares held by top holders
HolderShares% Held
Fullerton Fund Management Co. Ltd.as of 29 Sep 202126.02m5.84%
Qatar Investment Authority (Investment Management)as of 28 Sep 202110.33m2.32%
Data from 30 Sep 2022 - 01 Nov 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.